{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:25:11Z","timestamp":1787955911608,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Adv Skin Wound Care"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Rosacea is a chronic inflammatory disease characterized by a diverse set of nonspecific clinical signs including erythema, flushing, papules and pustules, skin thickening (especially enlarged nose) and thread-like vessels in the central facial region, and potential ocular involvement. This review focuses on the epidemiology, clinical presentation, and treatment of rosacea. Other related topics discussed include the psychosocial impact and differential diagnoses.<\/jats:p>\n          <jats:sec>\n            <jats:title>GENERAL PURPOSE<\/jats:title>\n            <jats:p>To review the clinical presentation and treatment of rosacea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>TARGET AUDIENCE<\/jats:title>\n            <jats:p>This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LEARNING OBJECTIVES\/OUTCOMES<\/jats:title>\n            <jats:p>After participating in this educational activity, the participant will:<\/jats:p>\n            <jats:p>1. Distinguish the clinical manifestations of rosacea subtypes.<\/jats:p>\n            <jats:p>2. Identify pharmacologic and nonpharmacologic treatment options for patients who have rosacea.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/asw.0000000000000065","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:00:48Z","timestamp":1700510448000},"page":"626-634","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Rosacea: Clinical Aspects and Treatments"],"prefix":"10.1097","volume":"36","author":[{"given":"Ryan","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn N.","family":"Bourkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gary","family":"Sibbald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"6 Suppl 1","key":"bib1-20250615","first-page":"S27","article-title":"Rosacea: current state of epidemiology","volume":"69","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"bib2-20250615","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","article-title":"Risk factors associated with rosacea","volume":"24","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"bib3-20250615","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"bib4-20250615","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjd.15122","article-title":"Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"bib5-20250615","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1203475416650427","article-title":"Canadian Clinical Practice Guidelines for Rosacea","volume":"20","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"bib6-20250615","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","article-title":"Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience","volume":"80","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"bib7-20250615","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"50","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"bib10-20250615","first-page":"29","article-title":"Pathogenesis of rosacea","volume":"17","year":"2001","journal-title":"Adv Dermatol"},{"issue":"3","key":"bib11-20250615","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea. Pathophysiology and treatment","volume":"130","year":"1994","journal-title":"Arch Dermatol"},{"issue":"6","key":"bib12-20250615","first-page":"1344","article-title":"Clinical characteristics and epidermal barrier function of papulopustular rosacea: a comparison study with acne vulgaris","volume":"32","year":"2016","journal-title":"Pak J Med Sci"},{"issue":"3","key":"bib13-20250615","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","article-title":"Rosacea: I. Etiology, pathogenesis, and subtype classification","volume":"51","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"bib14-20250615","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00006534-200209010-00023","article-title":"Rhinophyma: review and update","volume":"110","year":"2002","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"bib15-20250615","first-page":"389","article-title":"Actinic rhinophyma: an old disorder with a new name","volume":"57","year":"1996","journal-title":"Cutis"},{"issue":"4","key":"bib16-20250615","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-2008-1064456","article-title":"Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities","volume":"14","year":"1998","journal-title":"Facial Plast Surg"},{"issue":"1","key":"bib17-20250615","doi-asserted-by":"crossref","first-page":"e1361574","DOI":"10.1080\/19381980.2017.1361574","article-title":"Rosacea: epidemiology, pathogenesis, and treatment","volume":"9","year":"2017","journal-title":"Dermatoendocrinol"},{"issue":"3","key":"bib18-20250615","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0039-6257(86)90034-2","article-title":"Ocular rosacea","volume":"31","year":"1986","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"bib19-20250615","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1468-3083.2005.01216.x","article-title":"Rosacea and its management: an overview","volume":"19","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"bib20-20250615","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2013.05.019","article-title":"Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel","volume":"69","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"bib21-20250615","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"bib23-20250615","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1060028017740139","article-title":"Role of topical oxymetazoline for management of erythematotelangiectatic rosacea","volume":"52","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"3","key":"bib24-20250615","first-page":"544","article-title":"Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline","volume":"8","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"bib25-20250615","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"bib26-20250615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-4362.1993.tb00974.x","article-title":"Treatment of rosacea: topical clindamycin versus oral tetracycline","volume":"32","year":"1993","journal-title":"Int J Dermatol"},{"issue":"4","key":"bib27-20250615","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archderm.1976.01630280071021","article-title":"Letter: topically applied erythromycin in rosacea","volume":"112","year":"1976","journal-title":"Arch Dermatol"},{"issue":"3","key":"bib28-20250615","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0190-9622(98)70337-8","article-title":"The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial","volume":"39","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"bib29-20250615","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-4632.2004.02130.x","article-title":"Adapalene vs. metronidazole gel for the treatment of rosacea","volume":"44","year":"2005","journal-title":"Int J Dermatol"},{"issue":"5","key":"bib30-20250615","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"bib31-20250615","first-page":"CD003262","article-title":"Interventions for rosacea","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"bib32-20250615","first-page":"129","article-title":"Safety and efficacy of doxycycline in the treatment of rosacea","volume":"2","year":"2009","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7733","key":"bib33-20250615","first-page":"1049","article-title":"Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial","volume":"2","year":"1971","journal-title":"Lancet"},{"issue":"1","key":"bib34-20250615","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0002-9394(14)71750-7","article-title":"Efficacy of doxycycline and tetracycline in ocular rosacea","volume":"116","year":"1993","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"bib35-20250615","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"6053","key":"bib36-20250615","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/bmj.1.6053.105","article-title":"Clonidine and facial flushing in rosacea","volume":"1","year":"1977","journal-title":"Br Med J"},{"issue":"7","key":"bib37-20250615","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archderm.134.7.884","article-title":"Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea","volume":"134","year":"1998","journal-title":"Arch Dermatol"},{"issue":"1","key":"bib38-20250615","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555641521","article-title":"13-cis-Retinoic acid in rosacea. Clinical and laboratory findings","volume":"64","year":"1984","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"bib39-20250615","first-page":"522","article-title":"Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema","volume":"17","year":"1991","journal-title":"J Dermatol Surg Oncol"},{"issue":"2","key":"bib40-20250615","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14628839950516922","article-title":"Treatment of facial vascular lesions with intense pulsed light","volume":"1","year":"1999","journal-title":"J Cutan Laser Ther"},{"issue":"6","key":"bib41-20250615","doi-asserted-by":"crossref","first-page":"e2620","DOI":"10.1097\/GOX.0000000000002620","article-title":"A safe, modern treatment of rhinophyma: the 5-step technique","volume":"8","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:00:28Z","timestamp":1750021228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/asw.0000000000000065","relation":{},"ISSN":["1538-8654","1527-7941"],"issn-type":[{"value":"1538-8654","type":"electronic"},{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}